| Scorecard |
|---|
|
2 / 5 Stars
|
|
Lipper
---
|
|
Zacks Investment Research
2
(Buy)
|
|
Standard & Poor's
---
|
|
TheStreet.com
A+
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Short | % Net | |
|---|---|---|---|
| Cash | 1.23 | 0.0 | 1.23 |
| Stocks | 79.18 | 0.0 | 79.18 |
| Bonds | 0.0 | 0.0 | 0.0 |
| Other | 0.46 | 0.0 | 0.45 |
| Foreign Bonds | 0.0 | 0.0 | 0.0 |
| Foreign Stocks | 19.13 | 0.0 | 19.13 |
| Convertible | 0.0 | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 | 0.0 |
Updated 03.31.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 03.31.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Pfizer Inc | PFE | 16.19 | 4.85 |
| Gilead Sciences Inc | GILD | 36.53 | 4.5 |
| Johnson & Johnson | JNJ | 21.03 | 4.25 |
| Roche Holding AG | RHHVF | 23.65 | 4.0 |
| Celgene Corporation | CELG | 48.67 | 3.97 |
| Novartis AG | NVSEF | 17.5 | 3.68 |
| Amgen Inc | AMGN | 21.82 | 3.53 |
| Bristol-Myers Squibb Company | BMY | 24.03 | 3.28 |
| Eli Lilly and Company | LLY | 10.97 | 3.27 |
| Sanofi | SAN | --- | 2.9 |
